Skip to main content
Delfa

← All assets

Nuedexta

4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

4

Ongoing

0

Recruiting

0

Completed

3

Sites

84

Countries

1

Endpoints

71

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 71 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
1
Phase 3
1
Phase 4
2

Trials by status

Completed
3
Terminated
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Behavior / neuropsychiatric
34
Caregiver / quality of life
12
Other (unclassified)
11
Safety / tolerability / PK
4
Global cognition
2
Memory
2
Executive function / language
2
Function / daily living
2
Other clinical outcomes
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 24 of 71 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neuropsychiatric Inventory (NPI)Behavior

20

Mini-Mental State Examination (MMSE)Cognition

2

ADCS-Activities of Daily Living (ADCS-ADL)Function

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

4 of 4

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT01584440Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

Nuedexta

Alzheimer’s disease

Alzheimer's diseasePh 2Completed44Jul 20141results
NCT00056524Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

Nuedexta

Alzheimer’s disease

Age 18-80Ph 3Completed39Jun 20071
NCT01832350Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease

Nuedexta

Alzheimer’s disease

Alzheimer's diseasePh 4Terminated1Dec 20158
PRISM IISafety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

Nuedexta

Mixed / unspecified dementia

Age ≥18Ph 4Completed1May 20153results

Showing 1-4 of 4 trials